ACRS
Aclaris Therapeutics, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$3.48
+6.10%Year over year
Reported trailing growth
- Revenue
- -51.0%
- EBITDA
- -30.2%
- EBIT
- +41.1%
- EPS
- +57.7%
- Free cash flow
- -33.2%
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -31.5%
- EBITDA
- -38.4%
- EPS
- -26.3%
Three-year CAGR
- Revenue
- -35.9%
- EBITDA
- -24.7%
- EBIT
- +46.2%
- Net income
- +50.8%
- EPS
- +69.0%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026